Source: FDA label
| Registered trials | 148 |
|---|---|
| Brand names | GLATIRAMER ACETATE |
Boxed warning: The FDA label for this compound includes a boxed warning, the FDA's strongest safety warning. See the full prescribing information for details.
Mechanism of Action
12.1 Mechanism of Action The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatiramer acetate is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS. This hypothesis is supported by findings of studies that have been carried out to explore the pathogenesis of experimental autoimmune encephalomyelitis, a condition induced in animals through immunization against central nerv
Multiple sclerosis can bring unpredictable relapses, and people newly diagnosed often want to know whether a treatment can reduce that unpredictability. Glatiramer acetate is one of the longer-standing options prescribed for this purpose.
Key takeaways
- Glatiramer acetate is approved for relapsing forms of multiple sclerosis, including clinically isolated syndrome and relapsing-remitting disease.
- Its exact mechanism is not fully understood, but it is thought to modify immune processes involved in MS.
- The label carries a boxed warning.
- More than 148 clinical trials have studied glatiramer acetate or involved it as a comparator or add-on therapy.
- FAERS reports most commonly involve MS relapse, injection site reactions, and fatigue, reflecting reported events rather than confirmed side effects.
What Glatiramer Is
Glatiramer acetate is marketed under the brand name Glatiramer Acetate and belongs to the class of disease-modifying therapies used in multiple sclerosis. Researchers believe it works by altering immune system activity thought to drive the disease process in MS, based partly on studies of an animal model of central nervous system autoimmunity. The precise way it produces benefit in patients is still not completely defined.
What Glatiramer Is Approved For
Glatiramer acetate is indicated for relapsing forms of multiple sclerosis in adults. This includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The product label includes a boxed warning, which prescribers and patients should be aware of alongside the approved indication.
What the Evidence Shows
Glatiramer acetate has been studied or referenced in more than 148 registered clinical trials. One completed phase 2 trial examined its long-term safety when combined with teriflunomide in people already using interferon-beta or glatiramer acetate for MS. A separate, non-interventional study is currently recruiting to compare various injectable and oral MS treatments, including glatiramer acetate, in a real-world setting.
Reported Side Effects
FAERS data show that the most frequently reported events in people taking glatiramer acetate relate to disease activity and injection-related reactions: MS relapse (5,393 reports) and drug ineffective (4,207), alongside injection site pain (5,378), injection site reaction (3,602), and injection site erythema (2,687). Fatigue (3,445) and dyspnoea (3,052) were also commonly reported. These figures reflect the number of reports submitted to a surveillance system and do not establish incidence rates or prove that glatiramer acetate caused the event.
FAQ
What is glatiramer acetate used for?
Glatiramer acetate is approved to treat relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It is administered as part of long-term disease management rather than for acute symptom relief.
How does glatiramer acetate work?
Its exact mechanism is not fully understood, but it is believed to modify immune processes thought to underlie multiple sclerosis. This understanding is based partly on research using an animal model of immune-mediated central nervous system disease.
Does glatiramer acetate have a boxed warning?
Yes, the FDA label for glatiramer acetate includes a boxed warning. Patients should discuss the specifics of this warning with their prescriber.
What are the most commonly reported side effects of glatiramer acetate?
The most frequently reported events in FDA adverse event reports include injection site reactions such as pain and erythema, along with fatigue and dyspnoea. MS relapse and reports of the drug being ineffective were also commonly logged. These are counts of submitted reports, not confirmed rates of occurrence.
Has glatiramer acetate been studied in clinical trials?
Yes, it has been part of more than 148 registered clinical trials. These include studies on long-term safety when combined with other MS therapies and ongoing observational research comparing it with other injectable and oral treatments.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: FDA drug label (DailyMed) ClinicalTrials.gov FDA FAERS adverse event reports
Updated 2026-11-07